Recent clinical reports have associated the loss of PTEN as a significant biomarker for patients who fail to respond to ICIs across several tumor types including GBM, as well as melanoma, gastrointestinal, and breast cancers (13, 14, 15, 16). The gene discussed is PTEN; the disease is glioblastoma.